AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $2.79 | N/A |
Market Cap | $809.57M | N/A |
Shares Outstanding | 290.17M | N/A |
Employees | 630.00 | N/A |